Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hyperuricemia Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase)

NCT04829435
View directory record Official record
Conditions
Hyperuricemia, Gout
Interventions
ALLN-346, Placebo
Drug
Lead sponsor
Allena Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics

NCT02956278
View directory record Official record
Conditions
Chronic Gout, Hyperuricemia
Interventions
Allopurinol, Placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Primary Prevention of Hypertension in Obese Adolescents

NCT00288158
View directory record Official record
Conditions
Obesity, Pre-Hypertension, Hyperuricemia
Interventions
Allopurinol, Probenecid, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
11 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.

NCT03927677
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
Xanthine Oxidase Inhibitor
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Jul 22, 2026, 11:10 PM EDT
Recruiting Phase 2 Interventional

Uric Acid Lowering Trial in Youth Onset T2D

NCT03899883
View directory record Official record
Conditions
Diabetic Kidney Disease, Hyperuricemia, Diabetes, Diabetes Mellitus, Type 2, Type2 Diabetes, Type 2 Diabetes Mellitus, Diabetic Nephropathies, Diabetes Complications
Interventions
Pegloticase 8 MG/ML [Krystexxa]
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 25 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Not applicable Interventional Results available

Effect of Reducing Uric Acid on Insulin Sensitivity and Oxidative Status

NCT01931527
View directory record Official record
Conditions
Obesity, Metabolic Syndrome, Hyperuricemia
Interventions
Rasburicase
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 3 Interventional Results available

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

NCT00230178
View directory record Official record
Conditions
Tumor Lysis Syndrome, Cancer, Hyperuricemia
Interventions
Rasburicase (SR29142), Allopurinol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
15
States / cities
Berkeley, California • Los Angeles, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2010 · Synced Jul 22, 2026, 11:10 PM EDT
Terminated Phase 2 Interventional Results available

Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease

NCT03865407
View directory record Official record
Conditions
Hyperuricemia, Chronic Kidney Diseases
Interventions
Allopurinol
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
2 Years to 20 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671

NCT04060173
View directory record Official record
Conditions
Hyperuricemia, Gout
Interventions
ABP-671, Placebo
Drug · Other
Lead sponsor
Atom Therapeutics Co., Ltd
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 2 Interventional

Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia

NCT01052987
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
Tranilast, Allopurinol, Combination - Tranilast and Allopurinol, 400 mg Allopurinol, High dose combination
Drug
Lead sponsor
Nuon Therapeutics, Inc.
Industry
Eligibility
21 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Honolulu, Hawaii • Evansville, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2011 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 2 Interventional

Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout

NCT01129648
View directory record Official record
Conditions
Gout
Interventions
Placebo, Allopurinol, BCX4208
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years to 69 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
18
States / cities
Scottsdale, Arizona • Irvine, California • South Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2012 · Synced Jul 22, 2026, 11:10 PM EDT
Terminated Phase 1 Interventional Results available

Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects.

NCT02187029
View directory record Official record
Conditions
Gout
Interventions
PF-06743649, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Miami, Florida • South Miami, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2016 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Tigulixostat on the Pharmacokinetics of Theophylline

NCT06189404
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
Tigulixostat, Theophylline
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 2 Interventional

Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients

NCT04040816
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
SAP-001
Drug
Lead sponsor
Shanton Pharma Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Birmingham, Alabama • Anaheim, California • South Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 2 Interventional Results available

Lowering Serum Uric Acid to Prevent Acute Kidney Injury

NCT00756964
View directory record Official record
Conditions
Hyperuricemia
Interventions
Rasburicase, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 2, 2012 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia

NCT03934099
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
LC350189 formulated capsule, Placebo
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 75 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
34
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Jul 22, 2026, 11:10 PM EDT
Completed No phase listed Observational

Genetics of Hyperuricemia Therapy in Hmong

NCT02371421
View directory record Official record
Conditions
Hyperuricemia, Gout
Interventions
Allopurinol
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 14, 2019 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects

NCT03906006
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
ABP-671, Placebo
Drug · Other
Lead sponsor
Atom Therapeutics Co., Ltd
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Jul 22, 2026, 11:10 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function

NCT06729853
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
SAP-001
Drug
Lead sponsor
Shanton Pharma Pte. Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Tampa, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Febuxostat in Participants With Gout

NCT00430248
View directory record Official record
Conditions
Gout
Interventions
Febuxostat, Allopurinol
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 85 Years
Enrollment
2,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
258
States / cities
Birmingham, Alabama • Hoover, Alabama • Hueytown, Alabama + 255 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Jul 22, 2026, 11:10 PM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)

NCT06846515
View directory record Official record
Conditions
Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
Interventions
AR882 50 mg, AR882 75 mg, Placebo
Drug
Lead sponsor
Arthrosi Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
83
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 2 Interventional

Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout

NCT05253833
View directory record Official record
Conditions
Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
Interventions
AR882 Dose 1, AR882 Dose 2, Allopurinol Tablet
Drug
Lead sponsor
Arthrosi Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Jul 22, 2026, 11:10 PM EDT
Completed No phase listed Observational

Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients

NCT00186940
View directory record Official record
Conditions
Leukemia, Lymphoma, Tumor Lysis Syndrome, Hyperuricemia
Interventions
Rasburicase
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
11
States / cities
Palo Alto, California • San Diego, California • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 2 Interventional

Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients

NCT01416402
View directory record Official record
Conditions
Hyperuricemia, Gout
Interventions
Arhalofenate, Febuxostat, Colchicine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Jul 22, 2026, 11:10 PM EDT